Notice of Proposed Sale · 144
Fennec Pharmaceuticals Inc.
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- FENNEC PHARMACEUTICALS INC.
- Issuer CIK
- 0001211583
- SEC file number
- 001-32295
- Phone
- (919) 636-4530
- Person for whose account securities are to be sold
- ROSTISLAV RAYKOV
- Relationships to issuer
- Director
- Street
- PO BOX 13628, 68 TW ALEXANDER DRIVE
- City
- Research Triangle Park
- State / country code
- NC
- Postal code
- 27709
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 9,599 | 99,987.02 | 34,737,030 | 07/01/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/01/2026 | Stock Option Exercise | ISSUER | 9,599 | N | 07/01/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| ROSTISLAV RAYKOV | Common | 06/01/2026 | 9,747 | 93,813.90 |
| ROSTISLAV RAYKOV | Common | 05/01/2026 | 10,781 | 69,761.69 |
Seller — prior-sale row 1, entry 1
- Name
- ROSTISLAV RAYKOV
- Street
- PO BOX 13628, 68 TW ALEXANDER DRIVE
- City
- Research Triangle Park
- State / country code
- NC
- Postal code
- 27709
Seller — prior-sale row 2, entry 1
- Name
- ROSTISLAV RAYKOV
- Street
- PO BOX 13628, 68 TW ALEXANDER DRIVE
- City
- Research Triangle Park
- State / country code
- NC
- Postal code
- 27709
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/01/2026
- Signed
- /s/ Rostislav Raykov
- Plan adoption dates
- 09/19/2025
Company context
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSIÒ.